Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART352-L in Spinal Fusion
NCT04378543Phase 2Unknown
- Sponsor
- Ankasa Regenerative Therapeutics, Inc.
- Start
- Sep 2020
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of ART352-L in degenerative spondylolisthesis (DS), sponsored by Ankasa Regenerative Therapeutics, Inc.. Status: unknown.
02
Drugs
ART352-L
03
Conditions
degenerative spondylolisthesis (DS)
Beyond the preview
Go deeper on NCT04378543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04378543.